Stiefel Laboratories Corporation is a specialty pharmaceutical company that develops dermatology products based on innovative delivery vehicles. Much of this work is done in close collaboration with practicing dermatologists. The goal is simple: improve the lives of patients.

The Stiefel Laboratories VERSAFOAM® formulations are just one example of this collaboration. They combine the unique delivery of medication with ease of use – an important component in treatments.

Stiefel Laboratories backs its products with superior service, information and support for dermatologists. Our top-rated sales and marketing staff has more than 250 experienced professionals who work with the physicians that write 90 percent of the dermatology prescriptions in the U.S.

Current products formulated with VERSAFOAM:

OLUX® delivers the super-potent topical corticosteroid clobetasol propionate in the VERSAFOAM-HF™ vehicle. OLUX is indicated for short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp, and for short-term topical treatment of mild to moderate plaque-type psoriasis of non-scalp regions excluding the face and intertriginous areas.

Treatment should be limited to 2 consecutive weeks. OLUX-E Foam has been shown to suppress the HPA axis.

Systemic absorption of topical corticosteroids has caused reversible hypothalamic-pituitary-adrenal (HPA) suppression with potential for glucocorticosteroid insufficiency after withdrawal of treatment.

The most common adverse events in clinical trials were headache and application-site reactions including burning, itching, and dryness.

Treatment should not exceed 4 consecutive weeks. VERDESO Foam has the potential to suppress the HPA axis.

EXTINA® Foam may result in contact sensitization, including photoallergenicity.